- Collaboration provides opportunity to build on Alexion’s more than two decades of complement leadership with expansion into RNAi-based therapies using Dicerna’s GalXC™ technology - - Agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results